Clinical value of antibodies in inflammatory bowel diseases
Autor: | Novikov Aa, Aleksandrova En, A I Parfenov, Galina Lukina |
---|---|
Jazyk: | ruština |
Rok vydání: | 2021 |
Předmět: |
History
antimicrobial antibodies autoantibodies Endocrinology Diabetes and Metabolism antibodies to peptide antigens Disease diagnostic and prognostic value Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Intestinal mucosa inflammatory bowel disease Genetic predisposition Medicine ulcerative colitis Crohn's disease biology business.industry Panca Autoantibody General Medicine medicine.disease biology.organism_classification Ulcerative colitis digestive system diseases crohn’s disease 030220 oncology & carcinogenesis Immunology 030211 gastroenterology & hepatology Family Practice business |
Zdroj: | Терапевтический архив, Vol 93, Iss 2, Pp 228-235 (2021) |
ISSN: | 2309-5342 0040-3660 |
Popis: | Inflammatory bowel disease IBD (Crohns disease CD, ulcerative colitis UC) immune-mediated diseases of the digestive tract of unknown etiology. The basis of the pathogenesis of IBD is a violation of the protective mechanisms of the intestinal barrier as a result of a complex interaction of environmental factors, a genetic predisposition and defects in the activation of the immune response in the lymphoid tissue of the intestinal mucosa. Three groups of antibodies are detected in the sera of IBD patients: autoantibodies, antimicrobial antibodies and antibodies to peptide antigens. In CD, the most useful diagnostic markers are ASCA; in UC patients pANCA. Antibodies are not among the diagnostic criteria for CD and UC, the diagnosis of which is traditionally made on the basis of a complex of clinical, radiological, endoscopic and histological signs, but can be used as useful additional non-invasive markers for early diagnosis, assessment of clinical phenotypes, prognosis and effectiveness of treatment of these diseases. |
Databáze: | OpenAIRE |
Externí odkaz: |